Rivera-Sánchez Y, Martínez-Maldonado M, Reyes-Constantino LR, Domínguez-Rodríguez Á, Márquez-Celedonio FG, Budar-Fernández LF, Moreno-Ley PI, Nachón-Acosta A, Martínez-Mier G

Language: Spanish
References: 17
Page: 64-70
PDF size: 253.88 Kb.

ABSTRACT

Introduction: Gastrointestinal symptoms are post-transplant side effects that appear to be related to multiple factors. The objective of the study was to determine the prevalence of gastrointestinal symptoms in a Mexican cohort of renal transplant recipients and their possible association with the immunosuppressive regimen. Material and methods: Renal transplant recipients older than 18 years of age with stable renal function were interviewed from 02/2019-05/2019. Gastrointestinal symptoms were evaluated using the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. Higher total scores indicate increased severity in symptoms. Differences in GSRS score were assessed for both total and specific symptom. A < 0.05 p was considered statistically significant. Results: 103 patients (male, 63.15%) were surveyed, average age 36.6 years, average post-transplant time 45.5 months. Ninety-two patients (91%) had a gastrointestinal symptom. The most common symptoms were hunger pain (65%), belching (49.5%) loose stools (42.7%). Female patients had a higher GSRS score than males (p < 0.05). Hemoglobin had a significant inverse correlation to the GSRS score (p < 0.05). Individual symptom analysis showed reverse correlations of hemoglobin with nausea, constipation and diarrhea. Immunosuppression (tacrolimus and doses > 1,000 mg/day of mycophenolate) had greater upper gastrointestinal symptomatology (p < 0.05). Conclusions: Most renal transplant recipients experience gastrointestinal symptoms. Introducing questionnaires such as GSRS allows physicians to obtain information about their patient's condition and make decisions in their control.

REFERENCES

1. Gil-Vernet S, Amado A, Ortega F et al. Gastrointestinal complications in renal transplant recipients: MITOS study. Transplant Proc. 2007; 39: 2190-2193.

2. Ponticelli C, Colombo D, Novara M et al. Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians. Transpl Int. 2010; 23: 1126-1134.

3. Savvidaki E, Papachristou E, Kazakopoulos P et al. Gastrointestinal disorders after renal transplantation. Transplant Proc. 2014; 46: 3183-3186.

4. Ekberg H, Kyllonen L, Madsen S et al. Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients. Transplantation. 2007; 83: 282-289.

5. Kleinman L, Kilburg A, Machnicki G et al. Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI. Qual Life Res. 2006; 15: 1223-1232.

6. Nagaraj N, Kahan B, Adler DG. Gastrointestinal complications in renal transplant patients: a large, single-center experience. Dig Dis Sci. 2007; 52: 3394-3395.

7. Remes-Troche JM. Síntomas gastrointestinales en México. Un estudio epidemiológico. 2015. Editorial ASECOM, México D.F. México. ISBN 978-607-96924-0-7.

8. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.

9. The Tricontinental Mycophenolate mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996; 61: 1029-1037.

10. Tierce JC, Porterfield-Baxa J, Petrilla A et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant. 2005; 19: 779-784.

11. Laftavi MR, Hai F, Feng L et al. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: Comparison between mycophenolate sodium and mycophenolate mofetil. Transplant Proc. 2011; 43: 478-481.

12. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of FK506 and CsA for immunosuppression after cadaveric kidney transplantation. Transplantation. 1997; 63: 977-983.

13. Martin-Valencia A, Perello-Carrascosa M, Seron-Micas D. Anemia en paciente trasplantado renal secundaria a infección por parvovirus B19. Nefrologia Sup Ext. 2012; 3 (5): 22-26.

14. Vanrenterghem Y, Ponticelli C, Morales JM. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003; 3: 835-845. ISSN 1600-6135.

15. Reyes H, Hernandez AM, Valverse S et al. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Ped Transp. 2010; 14: 746-752.

16. Pérez BC, Moyano EMC, Estepa AM, Crespo MR. Factores asociados a calidad de vida relacionada con la salud de pacientes trasplantados de riñón. Enferm Nefrol. 2015; 18 (3): 204-226.

17. Martinez-Mier G, Salazar-Ramirez A. The cost of gastrointestinal adverse events and the impact of dose-reductions/discontinuations on acute rejection in kidney transplant patients of mycophenolate mofetil-related compared to enteric-coated Mycophenolate sodium: a pharmacoeconomic study. Transplant Proc. 2016; 48 (2): 588-595.